Identification of indications for albumin administration in septic patients with liver cirrhosis
Main finding · 28-day deathResult — go to the resultHazard ratio 0.76 95% CI 0.61–0.94Authors' conclusion
Albumin infusion is associated with a reduction in mortality in septic patients with liver cirrhosis under specific circumstances.
Study context
- Population
- Septic patients with liver cirrhosis in the MIMIC-IV 2.0 ICU databaseincluded in the final analysis
- Participants
- 2,265 patients
- Exposure
- Daily albumin infusion vs no albumin
- Albuminn = 1,093
- Outcome
- 28-day mortality
- Follow-up
- 28 days
Methodological detailsmarginal structural Cox models, MIMIC-IV 2.0 database
- Marginal structural Cox models
- MIMIC-IV 2.0 database
Main finding
28-day death
Hazard ratio
0.76
95% CI 0.61–0.94
Albumin vs No albumin
HR 0.76 (95% CI 0.61–0.94)
As reported in the abstract
Observational data: associations, not effects.
Further findings
Overall 28-day mortality (whole cohort)
- Overall 28-day mortality
- 29.6%
Circumstances of greatest benefit from albumin initiation
- Greatest benefit when initiated on day of serum albumin 2.5–3.0 g/dL, serum lactate ≥2 mmol/L, mean arterial pressure (MAP) <60 mmHg, or vasopressor dose 0.2–0.3 mcg/kg/min (norepinephrine equivalent)
Original publication
Identification of indications for albumin administration in septic patients with liver cirrhosis. Crit Care. Published 28 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →